MarketCap
Facebook
X
Telegram
Generation Bio Co. Balance Sheet 2024-2011 | GBIO
Brief balance sheet overview of Generation Bio Co.
Balance sheet changes are traced across five available annual reports between 2020 and 2024.
Assets declined from $294.2 million to $231.2 million, or -21.4%. The contraction calls for context such as disposals, restructuring or weaker operations.
Liabilities grew faster than assets: +454.6% versus -21.4%. A substantial part of expansion was externally funded.
Equity finances 37.3% of the balance sheet, compared with 91.1% at the start. The cushion remains adequate.
Each unit of equity supports about 0.2x of net debt. Dependence on debt remains comfortable.
The cash reserve occupies 33% of the balance sheet, previously 22.1%. It is one marker of short-term resilience.
The accumulated result is -$703 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
What the balance sheet shows
Generation Bio Co.'s financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Generation Bio Co.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
17.3 M | 31.4 M | -17.2 M | -300 M | - | -15.1 M | -7.3 M | - | - | - | - | - | - | - |
Long Term Debt |
80.6 M | 89.8 M | 74.6 M | 76.2 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
13 M | 8.12 M | 7.09 M | 4.61 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 132 M | 119 M | - | - | - | - | - | - | - |
Total Current Liabilities |
35.1 M | 39.9 M | 19.2 M | 18.8 M | 11.2 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
145 M | 172 M | 93.8 M | 95 M | 26.1 M | 141 M | 125 M | - | - | - | - | - | - | - |
Deferred Revenue |
10.6 M | 12.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-703 M | -571 M | -445 M | -308 M | -189 M | -108 M | -47.1 M | - | - | - | - | - | - | - |
Total Assets |
231 M | 375 M | 376 M | 477 M | 294 M | 42.1 M | 83.5 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
76.3 M | 66.4 M | 98.9 M | 381 M | 64.9 M | 17.2 M | 9.47 M | - | - | - | - | - | - | - |
Book Value |
86.2 M | 203 M | 282 M | 382 M | 268 M | -98.6 M | -41.6 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
86.2 M | 203 M | 282 M | 382 M | 268 M | -98.6 M | -41.6 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Generation Bio Co.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
19.7 M | 75.6 M | 78.1 M | 80.6 M | 83 M | 85.3 M | 87.6 M | 89.8 M | 71 M | 72.5 M | 74.5 M | 74.6 M | 76.7 M | - | 75.9 M | 76.2 M | 42.3 M | 43.5 M | 44.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
71.3 M | 125 M | 128 M | 145 M | 144 M | 150 M | 154 M | 172 M | 150 M | 151 M | 152 M | 93.8 M | 94 M | - | 91.1 M | 95 M | 56.8 M | 57.4 M | 55.3 M | 26.1 M | 26.1 M | 26.1 M | 26.1 M | 25.1 M | 25.1 M | 25.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
149 K | 1.51 M | 2.11 M | 10.6 M | 11.5 M | 13.6 M | 12.8 M | 12.9 M | 12 M | 8.26 M | 5.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-744 M | -739 M | -718 M | -703 M | -682 M | -666 M | -646 M | -571 M | -536 M | -508 M | -477 M | -445 M | -412 M | - | -343 M | -308 M | -277 M | -245 M | -215 M | -189 M | -189 M | -189 M | -189 M | -108 M | -108 M | -108 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
122 M | 179 M | 201 M | 231 M | 249 M | 265 M | 286 M | 375 M | 381 M | 405 M | 431 M | 376 M | 403 M | - | 444 M | 477 M | 464 M | 491 M | 514 M | 294 M | 294 M | 294 M | 294 M | 42.1 M | 42.1 M | 42.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
21.9 M | 49.1 M | 50.9 M | 76.3 M | 21.7 M | 28.5 M | 35.5 M | 66.4 M | 99.1 M | 151 M | 101 M | 93.2 M | 140 M | 164 M | 343 M | 375 M | 394 M | 392 M | 366 M | 62.9 M | 62.9 M | 62.9 M | 62.9 M | 15.1 M | 15.1 M | 15.1 M | - | 9.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
50.6 M | 54.1 M | 73.3 M | 86.2 M | 104 M | 115 M | 132 M | 203 M | 232 M | 254 M | 279 M | 282 M | 309 M | - | 353 M | 382 M | 407 M | 433 M | 459 M | 268 M | 268 M | 268 M | 268 M | 17 M | 17 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
50.6 M | 54.1 M | 73.3 M | 86.2 M | 104 M | 115 M | 132 M | 203 M | 232 M | 254 M | 279 M | 282 M | 309 M | 325 M | 353 M | 382 M | 407 M | 433 M | 459 M | 268 M | 268 M | 268 M | 268 M | -98.6 M | -98.6 M | -98.6 M | -54.7 M | -41.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Generation Bio Co., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
Israel
Britain
Singapore
USA
China
Japan
Canada